What Is Tesamorelin?
Tesamorelin (Egrifta) is classified as a ghrh analog peptide. Stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
It is extensively evaluated in laboratory and clinical settings for its potential to drive visceral fat reduction, body recomposition. Researchers target Tesamorelin for its ability to interact with specific cellular and molecular pathways, making it a compound of significant interest across multiple therapeutic domains.
FDA-approved for lipodystrophy; GI side effects possible. Contraindicated in active malignancy.
How Does Tesamorelin Work?
Stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
At the molecular level, Tesamorelin operates through pathways characteristic of the GHRH Analog class. By interacting with target receptors and downstream signaling cascades, the compound initiates biological responses associated with visceral fat reduction, body recomposition.
Expected Research Timeline
Weeks 2–4
Early GH-related effects; initial fluid retention possible
Months 2–3
Measurable visceral fat reduction (avg 15% in FDA trial at this point)
Long-Term
Sustained visceral fat reduction and metabolic improvement; IGF-1 normalization
What Does the Research Say?
The following are key findings from peer-reviewed studies on Tesamorelin, indexed on PubMed and equivalent databases:
[1]Tesamorelin visceral fat reduction (FDA trial)
Falutz et al. (JAMA): Randomized, double-blind, placebo-controlled Phase 3 trial showing 15.2% reduction in visceral adipose tissue vs. 5% increase in placebo. FDA-approved indication.
Evidence: very strong[2]Tesamorelin 52-week extension study sustained VAT reduction
Falutz et al. (J. Clin. Endocrinol. Metab.): 52-week data confirming sustained 18% visceral fat reduction with continuous therapy, with reversal upon discontinuation.
Evidence: strong[3]Tesamorelin reduces liver fat in HIV lipodystrophy
Stanley et al. (Ann. Intern. Med.): RCT demonstrating tesamorelin reduces hepatic fat content in HIV-infected patients with abdominal fat accumulation.
Evidence: strong[4]Tesamorelin improves executive function in older adults
Baker et al.: GHRH treatment (tesamorelin) shows favorable effects on executive function and verbal memory in cognitively normal and mildly impaired older adults via IGF-1 elevation.
Evidence: moderate[5]Tesamorelin IGF-1 effects and body composition (Phase 3)
Phase 3 trial showing ~80% increase in IGF-1 levels, improved body image distress scores, and significant trunk fat reduction across multiple patient populations.
Evidence: strongSafety & Side Effects
FDA-approved for lipodystrophy; GI side effects possible. Contraindicated in active malignancy.
| Side Effect | Incidence | Severity |
|---|---|---|
| Fluid retention | ~15% of users | mild |
| Injection site reactions | ~12% of users | mild |
| Joint pain / arthralgia | ~8% of users | mild |
| Glucose elevation | ~5% of users | moderate |
FDA Status: Approved
Tesamorelin has received FDA approval for specific clinical indications. Off-label uses remain under investigation.
How Is Tesamorelin Used?
Route
SubQ
Dose Range
1000–1000 mcg
Frequency
7x/week
Cycle
12–12 wk
Timing: Morning
Notes: FDA-approved dose: 2mg SubQ daily. Prescription required.
All dosing information reflects parameters reported in published research literature and is not intended as clinical guidance. Usage of any peptide should be supervised by a qualified healthcare professional.
Tesamorelin vs. Related Compounds
| Compound | Primary Use |
|---|---|
| Tesamorelin(this page) | Visceral fat reduction, body recomposition |
| CJC-1295 | Muscle growth, fat loss, recovery |
| Ipamorelin | GH release, muscle growth, recovery without cortisol spike |
| Sermorelin | Muscle growth, recovery, sleep, anti-aging |
Where to Source Tesamorelin for Research
Purchasing ultra-high purity, laboratory-grade peptides is critical for verifiable research. We only recommend vendors providing independent, third-party HPLC Certificates of Analysis (COA).
Disclosure: PeptiDex may earn a commission from purchases. This does not affect our recommendations. We exclusively feature vendors that pass our strict quality verification protocols.
Frequently Asked Questions
What is Tesamorelin?
Tesamorelin is a ghrh analog peptide. Stimulates GH for fat metabolism. Binds to GHRH receptors on the pituitary gland to stimulate natural growth hormone production, specifically targeting visceral adipose tissue.
What are the primary research benefits of Tesamorelin?
Published research identifies primary mechanisms targeting: Visceral fat reduction, body recomposition. These findings come from 5+ peer-reviewed studies indexed in our database.
What is the half-life of Tesamorelin?
In published pharmacokinetic data, Tesamorelin demonstrates a half-life of approximately 0.43 hours.
Is Tesamorelin FDA approved?
Yes, Tesamorelin has received FDA approval for specific indications. However, many research applications and off-label uses are still under investigation.
What are common side effects of Tesamorelin?
Reported side effects in published literature include Fluid retention (~15% of users), Injection site reactions (~12% of users), Joint pain / arthralgia (~8% of users), Glucose elevation (~5% of users). Most are classified as mild in severity.
How is Tesamorelin administered?
In research settings, Tesamorelin is typically administered via SubQ. FDA-approved dose: 2mg SubQ daily. Prescription required.
Sources
- Tesamorelin visceral fat reduction (FDA trial). View on PubMed
- Tesamorelin 52-week extension study sustained VAT reduction. View on PubMed
- Tesamorelin reduces liver fat in HIV lipodystrophy. View on PubMed
- Tesamorelin improves executive function in older adults. View on PubMed
- Tesamorelin IGF-1 effects and body composition (Phase 3). View on PubMed